



Products and Services


Azure
Azure Analysis Services
Azure Batch
Azure Cloud Services
Azure Data Lake Storage
Azure Databricks (AI)

Industry


Health Provider

Organization Size

Small (1 - 49 employees)



Atgenomix SeqsLab is Taiwan's first cloud-based high-performance computing platform in DNA and RNA sequencing research. It was developed as part of an effort to boost the country's smart medical industry. It can accelerate the identification of precise medical solutions in vaccine development and treatment guidelines for COVID-19. To manage big data of genome sequencing analysis and computing power, improve the current genomic analysis workflows, and speed up the process of developing a safe and effective COVID-19 vaccine, Atgenomix works with Microsoft Azure big data and cloud core technology services on the Atgenomix SeqsLab product platform.



Creating an enterprise-class genome sequencing and efficient computing management platform with Azure Cloud Services

Atgenomix SeqsLab, Taiwan's first cloud-based high-performance computing platform in DNA and RNA sequencing research, was developed as part of an effort to boost the country's smart medical industry. It can accelerate the identification of precise medical solutions in vaccine development and treatment guidelines for COVID-19.

"With SeqsLab and the high-performance computing power of Azure, we want medical institutions to speed up the viral and host genome sequencing analysis of COVID-19," says Chang Ming Tai, a co-founder of [Atgenomix](#), the company that built the platform.

"This can provide critical information on how the virus mutates, conserves, and causes disease at the genetic level, and can help fast-track vaccine development and treatment delivery to alleviate the outbreak as well as to prevent the future pandemic."

Research teams will be able to harness the computing power of big data with Microsoft Azure and improve the current genomic analysis workflows, computing efficiency, detection accuracy, and data scale.

Moreover, the Bio-IT platform that runs on Azure can process genomic workloads in two or three hours what conventional research analysis methods can handle in a week.

Integrating medical research and cloud computing to help overcome the pandemic

Atgenomix was selected as the first Microsoft Accelerator in 2019, becoming a new Microsoft partner. Microsoft is optimistic about the future development of Atgenomix, inviting the company to join its AI solutions and becoming a close marketing partner to create more market opportunities.

According to Ken Sun, General Manager of Microsoft Taiwan, Microsoft and its partners are committed to helping those who are fighting the pandemic.

“This project blends medical research and cloud computing. It brings Taiwan’s distinct advantage of tech capabilities closer to the medical industry,” he says. “We look forward to doing our part to help the world to overcome this public health crisis and hope that new medical progress is made in the fight against COVID-19.”

With SeqsLab and the high-performance computing power of Azure, we want medical institutions to speed up the viral and host genome sequencing analysis of COVID-19.

Chang Ming Tai: Co-Founder
Atgenomix

This project blends medical research and cloud computing. It brings Taiwan’s distinct advantage of tech capabilities closer to the medical industry. We look forward to doing our part to help the world to overcome this public health crisis and hope that new medical progress is made in the fight against COVID-19.

Ken Sun: General Manager of Microsoft Taiwan
Atgenomix